Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Zuma, Branson Collaborate To Establish Disease Control Center In South Africa
South African President Jacob Zuma and Virgin Group founder and chair Richard Branson "intend [on] establishing a disease control centre in South Africa as soon as next year," SAPA/The Times reports. "Branson said the initiative, expected to be launched by March, would be 50 percent private and 50 percent government funded," the news service writes (7/22).
generic viagra online
St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM
IBM (NYSE: IBM) announced that St. Elizabeth Healthcare is connecting hospitals, clinics and physicians offices in Northern Kentucky in the state"s largest roll-out of electronic medical records to improve patient care and lower costs.
News of the day
Psychologists Meet To Share Research In Coventry
More than 140 psychologists are meeting at the University of Warwick on 9th July 2009 to hear the latest theories and research at the British Psychological Society"s Division of Counselling Psychology annual conference.
Mental Health

Figuring Out Who Will Benefit Most From A New Therapy For Multiple Sclerosis

In a recent phase II clinical trial, the drug alemtuzumab (Campath-1H) was found to be a highly effective treatment for individuals with early relapsing-remitting multiple sclerosis. However, a substantial proportion of the patients treated (30%) went on to develop another autoimmune disease, mostly thyroid autoimmunity. Now, Joanne Jones and colleagues, at the University of Cambridge, United Kingdom, have determined that individuals with higher levels of the soluble factor IL-21 in their blood prior to alemtuzumab treatment were those that went on to develop an autoimmune disease. Further analysis identified a mechanism by which IL-21 contributes to the development of autoimmunity and determined that in some patients the higher levels of IL-21 were genetically predetermined. The authors therefore suggest that measuring levels of IL-21 in the blood of individuals with early relapsing-remitting multiple sclerosis might identify those that would be at greatest risk of developing autoimmunity if treated with alemtuzumab. Terri Laufer and Gregory Wu, at the University of Pennsylvania, Philadelphia, further discuss the importance of this in an accompanying commentary, noting that determining one reason why some patients succumb to autoimmune disease after alemtuzumab treatment, while others do not, is likely to increase enthusiasm for this new therapeutic. TITLE: IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) AUTHOR CONTACT: Joanne L. Jones University of Cambridge, Addenbrooke"s Hospital, Cambridge, United Kingdom. View the PDF of this article at: https://www.the-jci.org/article.php?id=37878 ACCOMPANYING COMMENTARY TITLE: Treating MS: getting to know the two birds in the bush AUTHOR CONTACT: Terri M. Laufer University of Pennsylvania, Philadelphia, Pennsylvania, USA. View the PDF of this article at: https://www.the-jci.org/article.php?id=39963 Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009